Adipotide vs CagriSema
A side-by-side research comparison of Adipotide and CagriSema across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Adipotide | CagriSema |
|---|---|---|
| Full name | Adipotide (FTPP / Prohibitin-Targeting Peptide) | CagriSema (Cagrilintide + Semaglutide) |
| Category | Weight Management | Weight Management |
| Status | Research compound (preclinical) | Phase 3 Clinical Trial |
| Mechanism | A fusion of a prohibitin-targeting peptide and a pro-apoptotic sequence. It binds prohibitin on the vasculature that feeds white fat, inducing apoptosis of those blood vessels, which starves fat cells and causes them to be resorbed. | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. |
| Molecular weight | ~2.6 kDa | Combination product |
| Half-life | Short (hours) | 7 days (both components) |
| Bioavailability | Subcutaneous injection | High (SubQ) |
| Typical dose | Not established for human use | Cagrilintide 2.4mg + Semaglutide 2.4mg |
| Frequency | Research protocols only | Once weekly |
| Route | Subcutaneous injection | Subcutaneous |
Adipotide reported benefits
- Rapid targeted white-fat reduction (animal models)
- Weight loss without appetite suppression
- Reversal of metabolic markers in obese primates
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Related comparisons
Research and educational reference only. Not medical advice.